GlassScriptPhysician profile
Liautaud Prophete
NPI 1134219264
$4,105.68
in general payments reported to CMS, 2019-2025
31 companies · $545 in 2025
The $545 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $249 · 2021: $447 · 2022: $357 · 2023: $783 · 2024: $1,258 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.74 | 2019-2023 | |
| Mimedx Group, INC. | $445.45 | 2024-2025 | |
| Exact Sciences Corporation | $417.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $292.25 | 2023-2025 | |
| Astellas Pharma US INC | $212.16 | 2024-2025 | Veozah |
| Organon LLC | $173.65 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $165.32 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $164.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.35 | 2019-2023 | |
| Hologic Sales and Service, LLC | $130.64 | 2019-2024 | Aptima |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Edwards Lifesciences Corporation | $124.97 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $121.86 | 2019 | |
| Pfizer INC. | $105.69 | 2022-2023 | |
| Evofem Biosciences, INC. | $95.63 | 2023-2025 | Phexxi, Solosec, Phexx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $81.98 | 2024 | |
| Merck Sharp & Dohme LLC | $79.78 | 2019-2023 | Gardasil 9 |
| Coloplast Corp | $75.20 | 2024 | |
| Biogen, INC. | $66.21 | 2024-2025 | Zurzuvae |
| Corcept Therapeutics | $64.13 | 2024 | Korlym |
| Lupin INC. | $62.62 | 2019-2020 | |
| Minerva Surgical, INC | $61.28 | 2023-2025 | |
| Smith+Nephew, INC. | $53.92 | 2020-2025 | Stravix Pl |
| Agile Therapeutics, INC. | $52.61 | 2022-2023 | Twirla |
| Coopersurgical, INC. | $28.59 | 2021 | |
| Dexcom, INC. | $25.31 | 2024 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $23.20 | 2020 | |
| Aspira Women'S Health INC | $22.03 | 2022 | |
| Boston Scientific Corporation | $21.57 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.44 | 2019 | |
| Olympus America INC. | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liautaud Prophete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.